Fewer Injection Site Reactions In Patients Using AVONEX Versus Sub-cutaneous Interferon And Glatiramer Acetate For The Treatment Of Multiple Sclerosis

Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ®(interferon beta-1a).